FEATURE: Why biotech recruiters are confident in '04
08 January, 2004 by Melissa TrudingerThe slump in the Australian biotechnology industry in the first half of 2003 was reflected in the recruitment market, according to leading recruitment consultants.
AusBiotech hails 'exceptional' talent in new board line-up
16 December, 2003 by Melissa TrudingerAusBiotech members have elected Johnson & Johnson Research managing director Susan Pond, venture capitalist Leigh Farrell and former Amrad managing director Sandra Webb as corporate directors to its board, after a tight race between nine candidates. Western Australian Biomedical Research Institute director Simon Carroll was also re-elected as an institutional director.
Critical mass key to investor support: Vernalis CEO
09 December, 2003 by Melissa TrudingerSmall biotech companies face investor resistance to mergers and acquisitions, a leading British biotech CEO told attendees at a briefing in Melbourne on Tuesday.
Did BIF offer bang for its buck?
08 December, 2003 by Michael VitaleThe fifth round of Biotechnology Innovation Fund (BIF) grants, announced late last month by Federal Industry Minister Ian Macfarlane, is the final funding round for the $40 million program. Over its lifetime, the BIF scheme has supported 164 projects in 153 companies, ranging from tiny start-ups to listed giants such as Orica.
Peter Mac spin-off nets European funding
27 November, 2003 by Melissa TrudingerThe Peter MacCallum Cancer Centre has spun out its cellular therapies services into a small company called Cell Therapies, in order to make the most of its TGA-licensed Centre for Blood Cell Therapies.
British Columbia's Discovery Parks a good model for Australia
20 November, 2003 by Melissa TrudingerThe developer of British Columbia's Discovery Parks -- technology parks based on four campuses around the Canadian province -- believes the Discovery Park model would be advantageous to the development of Australian innovation and technology.
Strategic alliances between Victoria and China flagged
20 November, 2003 by Melissa TrudingerVictoria has signed a Memorandum of Understanding with Chinese sister state Jiangsu Province calling for strategic biotechnology alliances and joint ventures.
Academics should not fear industry involvement, says Canadian prof
20 November, 2003 by Melissa TrudingerAcademic researchers need a bit of encouragement to take the plunge into biotechnology, according to visiting University of British Columbia professor and biotechnology company founder Bob Hancock.
Dendritic Nanotechnologies granted self-assembly patents, gets funding boost
19 November, 2003 by Graeme O'NeillLeading US nanotechnology innovator Dendritic Nanotechnologies (DNT) continues to shine for its associate and 49.9 per cent owner Melbourne drug-developer Starpharma (ASX: SPL), after being granted a US patent on a new self-assembly technique for its giant, branched molecules, called dendrimers.
NZ's Blis targets Chinese market
04 November, 2003 by Graeme O'NeillDunedin biotech Blis Technologies has opened a portal into a potential AUD$200 million market by signing a deal with Auckland-based Asia-Pacific Biotech Distributors to take its antibacterial Throat Guard into China.
Ventracor raises $33m in rights issue
29 October, 2003 by Melissa TrudingerVentracor (ASX:VCR) has closed its renounceable rights issue, raising approximately AUD$33 million in an offer oversubscribed by $12 million.
Amrad aims to regain its footing
27 October, 2003 by Melissa TrudingerIf you'd asked him a year ago whether he could see himself as CEO of Amrad, Dr Peter Smith would have said not likely.
Gradipore faces shareholder-driven rebellion
24 October, 2003 by Melissa TrudingerJust weeks after a new CEO was appointed, embattled bioseparations company Gradipore has lost almost its entire board of directors in a shareholder-driven rebellion against the management of the company.
AusBiotech appoints policy and comms officer
15 October, 2003 by Melissa TrudingerIndustry association AusBiotech is moving to cement its role as an advocate for Australia's biotechnology industry, with the appointment of former SDA Biotech principal Paris Brooke to a newly created role in policy and communications.
Tight budget at Monash forces Metabolic sell-off
15 October, 2003 by Graeme O'NeillIn a drastic move to raise more funds for medical research, Monash University has sold off 6 million of its shares in promising Victorian biotech Metabolic Pharmaceuticals (ASX:MBP).
